Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/61801
Tipo: Artigo de Periódico
Título: Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
Autor(es): Carla Boquimpani
Fernanda Salles Seguro
Gustavo Henrique Romani Magalhães
Ingrid Luise Soares Pinto
Israel Bendit
Jaisson André Pagnoncelli Bortolini
Katia Borgia Barbosa Pagnano
Renato Centrone
Vaneuza Funke
Resumen: Introduction Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil, for example, molecular tests (BCR::ABL1) are not broadly available, making it difficult to monitor the patients adequately. Objective In this sense, providing TFR recommendations for Brazilian physicians are therefore necessary. These recommendations include the main criteria checklist to start the TKIs treatment discontinuing process in patients diagnosed with CML and the population-eligible characteristics for treatment discontinuation. Method Age, risk score at diagnosis, TKI treatment duration, BCR::ABL1 transcripts type, depth of the molecular response for treatment discontinuation, treatment adherence, patient monitoring and withdrawal syndrome are essential factors to consider in TFR. After TKI discontinuation, BCR::ABL1 transcripts monitoring should be more frequent. When a major molecular response loss is observed during the monitoring of a patient in TFR, the TKI treatment should be resumed.
Asunto: Neoplasias
Guia de Prática Clínica
Terapêutica
Idioma: eng
País: Brasil
Editor: Universidade Federal de Minas Gerais
Sigla da Institución: UFMG
Departamento: MEDICINA - FACULDADE DE MEDICINA
Tipo de acceso: Acesso Aberto
Identificador DOI: https://doi.org/10.1016/j.htct.2022.04.002
URI: http://hdl.handle.net/1843/61801
Fecha del documento: 2022
metadata.dc.url.externa: https://www.sciencedirect.com/science/article/pii/S2531137922000505?via%3Dihub
metadata.dc.relation.ispartof: Hematology, Transfusion and Cell Therapy
Aparece en las colecciones:Artigo de Periódico



Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.